Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Low frequency of p16 INK4a promoter methylation in mammary carcinomas as revealed by positive display of methylated sites

Authors: R Lilischkis, H Kneitz, H Kreipe

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Promoter methylation represents an important mechanism for silencing gene expression in higher eukaryotes. In order to study methylation of the promoter of the tumour suppressor p16 INK4a, we developed a fast and simple method that in contrast to previous studies relies on the positive display of methylated sites (PDM). The method is based on bisulphite treatment of DNA, PCR-amplification of the modified DNA, and restriction digest of de novo created restriction sites to positively display DNA methylation in a background of unmethylated DNA. Since methylated as well as unmethylated DNA is amplified, information on the proportion of both is provided. …
Metadata
Title
Low frequency of p16 INK4a promoter methylation in mammary carcinomas as revealed by positive display of methylated sites
Authors
R Lilischkis
H Kneitz
H Kreipe
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr118

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Oral presentation

Telomerase: a breast cancer chemopreventive and therapeutic target

Oral presentation

Two molecular cytogenetic views of breast cancer

Oral presentation

Molecular control of apoptosis in the breast

Meeting abstract

Role of the breast cancer susceptibility gene BRCA1 in radio-resistance

Meeting abstract

Clinical and pathological characteristics in patients with BRCA1/2-mutation associated with breast cancer (BC) with a long clinical follow-up

Meeting abstract

Germline TP53mutations in Finnish breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits